14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
ANTX vs SIGA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, AN2 Therapeutics, Inc. (ANTX) captures the overall head-to-head institutional edge over SIGA Technologies Inc. (SIGA) on higher Unified Composite conviction (37.2/100 SELL vs. 47.5/100 HOLD) after splitting the core matrix 3–5 (led by Growth & Scale), while SIGA wins 4–1 across the 6-pillar growth and valuation breakdown. ANTX trades at $5.22 (N/M Forward P/E, 0.0% operating margin) versus SIGA at $2.65 (2.5x Forward P/E, -14.2% operating margin).
Composite vs. Pillar Nuance: While SIGA currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. ANTX 37.2/100 SELL), ANTX captures the overall institutional head-to-head verdict (3–5 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -14.2% operating margin) and revenue trajectory (+0.0% vs. -49.7% YoY).
Technical & Structure Timing Caution: ANTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.0); meanwhile SIGA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANTX vs SIGA. Trailing 12-month operating profitability (ANTX 0.0% vs SIGA -14.2%) and valuation multiples (ANTX N/M vs SIGA 2.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $187.9M market capitalization and -14.2% operating margin.
OpEx & R&D Reinvestment37.6% of Rev ($20M)
90D Engineering Disclosures0 Published
Investor FAQ ANTX vs SIGA Key Questions & Quantitative Answers
As of Nov 19, 2026, AN2 Therapeutics, Inc. (ANTX) captures the overall head-to-head institutional edge over SIGA Technologies Inc. (SIGA) on higher Unified Composite conviction (37.2/100 SELL vs. 47.5/100 HOLD) after splitting the core matrix 3–5 (led by Growth & Scale), while SIGA wins 4–1 across the 6-pillar growth and valuation breakdown. ANTX trades at $5.22 (N/M Forward P/E, 0.0% operating margin) versus SIGA at $2.65 (2.5x Forward P/E, -14.2% operating margin). Composite vs. Pillar Nuance: While SIGA currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. ANTX 37.2/100 SELL), ANTX captures the overall institutional head-to-head verdict (3–5 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -14.2% operating margin) and revenue trajectory (+0.0% vs. -49.7% YoY). Technical & Structure Timing Caution: ANTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.0); meanwhile SIGA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ANTX leads the Growth & Scale pillar: ANTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SIGA at -49.7% YoY revenue growth and -65.3% YoY earnings growth on $52M TTM revenue (23.4% gross margin, -14.2% operating margin). On trailing 12-month operating scale, ANTX generates N/A in USD-normalized revenue versus $52M for SIGA. In operating R&D and SG&A reinvestment, ANTX deploys N/A (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($20M) (0 disclosures) for SIGA.
SIGA screens cheaper on headline valuation multiples. ANTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SIGA trades at 2.5x Forward P/E, N/M Trailing P/E, 3.37x PEG, and 1.4x EV/Revenue (-22.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANTX (-51.3% ROE) versus SIGA (0.4% ROE) capital efficiency.
In options market volatility and institutional positioning, ANTX carries 134.2% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 98% Vol realized risk). By comparison, SIGA carries 81.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 65% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.